how do you know which cryptocurrency to buy Top People also ask

On the 13th, the No.20 rubber fell by 2.05%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract No.20 rubber 2502 was closed, with a turnover of 159,100 lots. The position data showed that the top 20 seats were clear, and the difference position was 5,142 lots. A total of 205,200 lots were traded in the No.20 rubber futures contract, an increase of 8,176 lots over the previous day. The first 20 seats in the contract held 84,200 lots, an increase of 812 lots over the previous day. Short positions in the top 20 seats of the contract were 94,500 lots, a decrease of 1,708 lots from the previous day. (Sina Futures)Ali launched the e-commerce app "Tao" in Japan: in the future, it will expand its staff to explore the local market. On December 12, Alibaba Group held a briefing on the e-commerce app "Tao" launched for the Japanese market. The company said that it will expand its staff in the future and fully explore the Japanese market. According to reports, the APP was launched in October, selling more than 3 million kinds of goods such as clothing, groceries and digital related products. It also has the function of recommending goods by artificial intelligence (AI) according to consumers' preferences. The goods are mainly delivered from China after the consumer places an order, and arrive in Japan a few days later. (Interface News)To ensure that patients across the country will use the drugs selected in April next year, the tenth batch of drugs organized by the state will be opened for centralized procurement, and the tenth batch of drugs organized by the state will be selected in Shanghai yesterday, and 62 drugs will be purchased successfully. Covering hypertension, diabetes, tumors, cardiovascular and cerebrovascular diseases, infections, mental diseases and other fields. In the next step, the National Medical Insurance Bureau will guide local and selected enterprises to do a good job in the implementation of the selected results to ensure that patients across the country can use the selected products in this centralized collection in April 2025. (CCTV News)

Hisense Jia Shaoqian: Brand building is very hard work, which requires long-term persistence and a lot of money. The annual meeting of Caijing 2025: Forecast and Strategy and 2024 Global Wealth Management Forum was held in Beijing from December 13th to December 15th. Jia Shaoqian, Chairman of Hisense Group, delivered a speech. Jia Shaoqian pointed out that whether it is globalization or transformation, the key to the success of strategy lies in persistence and implementation to the end. He bluntly said that branding is a very hard job, which requires long-term persistence and a lot of money. Hisense firmly believes in the power of brands, that brands are the future of enterprises, and that there is no internationalization of Hisense without the internationalization of brands. "Especially when most China enterprises take advantage of the dividends from entering the market and borrow ships to go out to sea through OEM to make quick money, Hisense voluntarily gave up OEM and chose the most difficult shipbuilding to go out to sea, that is, resolutely went to the high end and invested a lot of money, people and resources in brand building, especially in corporate marketing." He said. (Rui Jian)Deputy Director Huang Huabo attended the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group. On December 12, 2024, the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group was held in Beijing. Huang Huabo, chairman of the working group, member of the party group and deputy director of the National Health Insurance Bureau, attended and spoke. The symposium summarized the work results of the National Working Group on Medical Security Standardization in 2024, and discussed the work in 2025, the five-year development plan of medical security standardization, the framework system and relevant medical insurance standards. Huang Huabo pointed out that in 2024, with the guidance of the National Standards Committee and the support of the bureau party group, all the work of the working group was smoothly promoted through the joint efforts of all members and relevant units inside and outside the bureau. In 2025, the high-quality development of medical insurance put forward higher requirements for medical insurance standardization. It is necessary to further strengthen the sense of responsibility, professionalism and cooperation, accelerate the construction of medical insurance standardization team, and play a supporting role for the high-quality development of medical insurance. (National Medical Insurance Bureau)Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.

Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Centaline Property: The price of second-hand houses in Hong Kong dropped by 0.6% on a weekly basis. Centaline Property said on its website that in the week from December 2 to 8, the leading index of Central Plains cities, which measures the price of second-hand houses in Hong Kong, fell by 0.6% to 137.59.Hailide: PPS filament products have not yet been involved in the field of humanoid robots. Hailide said on the interactive platform on December 13th that the company has been deeply involved in the field of materials for many years, and with the continuous investment in research and development, the commercialization of PPS filament has been realized. At present, the product has not yet been involved in the field of humanoid robots. In the future, the company will strive to gradually realize mass production applications in related emerging fields, and is full of confidence in this.